Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932451 · ClinicalTrials.gov registry record · Phase 2
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,069
- Enrollment target
NCT00932451: Completed Phase 2 study, sponsored by Pfizer.
NCT00932451 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 1,069 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (704% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00932451, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,069 participants
- Enrollment target
Study Summary
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081007) to receive PF-02341066.
Primary Outcome
The objective response rate (ORR) as a measure of anti-tumor efficacy of oral PF-02341066 in participants with advanced NSCLC with an ALK gene translocation or inversion after failure of at least one line of chemotherapy.
Interventions
- DRUG PF-02341066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,069 participants |
| Start Date | 2010-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
What the finished NCT00932451 record still lists
NCT00932451 is an interventional study that assigns participants to a tested intervention. Its 1,069 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (704% higher).
The record links to 0 conditions, and to 1 intervention - of which PF-02341066 is the first listed.
NCT00932451 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00932451 about?
NCT00932451 is a clinical study titled "An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene". This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081...
What is the current status of trial NCT00932451?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,069 participants. The study started on 2010-01. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00932451?
The interventions under investigation include: PF-02341066 (DRUG).
Who is sponsoring clinical trial NCT00932451?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00932451's enrollment target sits among peer trials
1,069 24th of 2000 higher than 1,977 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06751043 · 1,072 participants · NA
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
- NCT04165798 · 1,065 participants
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- NCT06159673 · 1,074 participants · Phase 2
ACP-204 in Adults With Alzheimer's Disease Psychosis
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia